China Oncology ›› 2022, Vol. 32 ›› Issue (6): 478-486.doi: 10.19401/j.cnki.1007-3639.2022.06.002
• Specialists' Commentary • Previous Articles Next Articles
SU Chunxia()(), ZHOU Caicun()()
Received:
2022-05-27
Revised:
2022-06-10
Online:
2022-06-30
Published:
2022-07-21
Contact:
ZHOU Caicun
E-mail:susu_mail@126.com;caicunzhoudr@163.com
CLC Number:
SU Chunxia, ZHOU Caicun. Current status and future directions of immunotherapy for advanced non-small cell lung cancer[J]. China Oncology, 2022, 32(6): 478-486.
[1] | ZHENG R S,, ZHANG S W,, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. |
[2] |
MOLINA J R,, YANG P,, CASSIVI S D, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship[J]. Mayo Clin Proc, 2008, 83(5): 584-594.
doi: 10.1016/S0025-6196(11)60735-0 |
[3] |
YANG C Y,, YANG J C H,, YANG P C. Precision management of advanced non-small cell lung cancer[J]. Annu Rev Med, 2020, 71: 117-136.
doi: 10.1146/annurev-med-051718-013524 |
[4] |
RECK M,, RODRÍGUEZ-ABREU D,, ROBINSON A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833.
doi: 10.1056/NEJMoa1606774 |
[5] | BRAHMER J R,, RODRIGUEZ-ABREU D,, ROBINSON A G, et al. LBA51 KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%[J]. Ann Oncol, 2020, 31: S1181-S1182. |
[6] |
HERBST R S,, GIACCONE G,, DE MARINIS F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC[J]. N Engl J Med, 2020, 383(14): 1328-1339.
doi: 10.1056/NEJMoa1917346 |
[7] |
JASSEM J,, DE MARINIS F,, GIACCONE G, et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC[J]. J Thorac Oncol, 2021, 16(11): 1872-1882.
doi: 10.1016/j.jtho.2021.06.019 |
[8] |
SEZER A,, KILICKAP S,, GÜMÜŞ M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial[J]. Lancet, 2021, 397(10274): 592-604.
doi: 10.1016/S0140-6736(21)00228-2 |
[9] |
RECK M,, RODRÍGUEZ-ABREU D,, ROBINSON A G, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50[J]. J Clin Oncol, 2021, 39(21): 2339-2349.
doi: 10.1200/JCO.21.00174 |
[10] |
HWANG D M,, ALBAQER T,, SANTIAGO R C, et al. Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer[J]. J Thorac Oncol, 2021, 16(9): 1490-1500.
doi: 10.1016/j.jtho.2021.03.028 |
[11] |
GANDHI L,, RODRÍGUEZ-ABREU D,, GADGEEL S, et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092.
doi: 10.1056/NEJMoa1801005 |
[12] | GADGEEL S,, GARASSINO M C,, ESTEBAN E, et al. KEYNOTE-189: OS update and progression after the next line of therapy (PFS2) with pembrolizumab + chemotherapy for metastatic nonsquamous NSCLC[J]. J Thorac Oncol, 2019, 14(11): S1153. |
[13] |
PAZ-ARES L,, LUFT A,, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051.
doi: 10.1056/NEJMoa1810865 |
[14] |
PAZ-ARES L,, VICENTE D,, TAFRESHI A, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407[J]. J Thorac Oncol, 2020, 15(10): 1657-1669.
doi: 10.1016/j.jtho.2020.06.015 |
[15] |
ZHOU C C,, CHEN G Y,, HUANG Y C, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3): 305-314.
doi: 10.1016/S2213-2600(20)30365-9 |
[16] |
YANG Y P,, WANG Z H,, FANG J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology program by innovent anti-PD-1-11)[J]. J Thorac Oncol, 2020, 15(10): 1636-1646.
doi: 10.1016/j.jtho.2020.07.014 |
[17] |
YANG Y P,, SUN J Y,, WANG Z H, et al. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study[J]. J Thorac Oncol, 2021, 16(12): 2109-2120.
doi: 10.1016/j.jtho.2021.07.015 |
[18] |
LU S,, WANG J,, YU Y, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial[J]. J Thorac Oncol, 2021, 16(9): 1512-1522.
doi: 10.1016/j.jtho.2021.05.005 |
[19] | ZHOU C,, REN S,, CHEN J, et al. Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): a randomized, double-blind, multicenter, phase Ⅲ trial[J]. J Thorac Oncol, 2021, 16(4): S748. |
[20] | WANG J,, LU S,, HU C, et al. Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)[J]. Ann Oncol, 2020, 31: S817. |
[21] |
ZHOU C C,, WU L,, FAN Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)[J]. J Thorac Oncol, 2021, 16(9): 1501-1511.
doi: 10.1016/j.jtho.2021.04.011 |
[22] |
ZHOU C C,, WANG Z P,, SUN Y P, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial[J]. Lancet Oncol, 2022, 23(2): 220-233.
doi: 10.1016/S1470-2045(21)00650-1 |
[23] | WANG J,, WANG Z,, WU L, et al. CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC[J]. J Thorac Oncol, 2021, 16(10): S927-S928. |
[24] | RECK M,, JOTTE R,, CAPPUZZO F, et al. IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)[J]. Pneumologie, 2020, 74: S39-S39 |
[25] | YANG J C H,, LUFT A,, DE LA MORA JIMÉNEZ E, et al. Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): a phase Ⅲ, randomized, double-blind study[J]. Ann Oncol, 2021, 32: S1429-S1430. |
[26] | NISHIO M,, PELED N,, ZER A, et al. Phase Ⅲ LEAP-006 safety Run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC[J]. Ann Oncol, 2020, 31: S848-S849. |
[27] | REN S X,, HE J X,, FANG Y, et al. Camrelizumab plus apatinib in treatment-naive patients with advanced nonsquamous NSCLC: a multicenter, open-label, single-arm, phase 2 trial[J]. JTO Clin Res Rep, 2022, 3(5): 100312. |
[28] | HAN B H,, CHEN J,, XIE Q, et al. A multicenter, randomized, phase 3 trial of penpulimab in combination with anlotinib or chemotherapy as first-line treatment in advanced NSCLC[J]. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, 2021, 16(3): S650. |
[29] |
CHU T Q,, ZHONG R B,, ZHONG H, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC[J]. J Thorac Oncol, 2021, 16(4): 643-652.
doi: 10.1016/j.jtho.2020.11.026 |
[30] |
ZHAO S,, REN S X,, JIANG T, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer[J]. Cancer Immunol Res, 2019, 7(4): 630-643.
doi: 10.1158/2326-6066.CIR-17-0640 |
[31] |
HELLMANN M D,, PAZ-ARES L,, BERNABE CARO R, et al. Nivolumab plus ipilimumab in advanced non-small cell lung cancer[J]. N Engl J Med, 2019, 381(21): 2020-2031.
doi: 10.1056/NEJMoa1910231 |
[32] |
PAZ-ARES L G,, RAMALINGAM S S,, CIULEANU T E, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial[J]. J Thorac Oncol, 2022, 17(2): 289-308.
doi: 10.1016/j.jtho.2021.09.010 |
[33] |
PAZ-ARES L,, CIULEANU T E,, COBO M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2): 198-211.
doi: 10.1016/S1470-2045(20)30641-0 |
[34] | JOHN T,, SAKAI H,, IKEDA S, et al. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA[J]. Ann Oncol, 2020, 31: S847-S848. |
[35] | JOHNSON M,, CHO B C,, LUFT A, et al. Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study[J]. J Thorac Oncol, 2021, 16(10): S844. |
[36] | ABREU D R,, RECK M,, ŞENDUR N, et al. Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up[J]. Ann Oncol, 2022, 33: S30-S31. |
[37] | MARUHASHI T,, SUGIURA D,, OKAZAKI I M, et al. LAG-3: from molecular functions to clinical applications[J]. J Immunother Cancer, 2020, 8(2): e001014. |
[38] | HODI F S,, TAWBI H A,, LIPSON E J, et al. Relatlimab (RELA) + nivolumab (NIVO) vs NIVO in previously untreated metastatic or unresectable melanoma: additional efficacy in RELATIVITY-047[J]. Ann Oncol, 2021, 32: S867-S868. |
[39] | MORGENSZTERN D,, CHAUDHRY A,, IANNOTTI N, et al. RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs NIVO with chemotherapy in stage Ⅳ or recurrent non-small cell lung cancer (NSCLC): a phase Ⅱ, randomized, double-blind study[J]. Ann Oncol, 2021, 32: S1030. |
[40] | CHAUVIN J M,, ZAROUR H M. TIGIT in cancer immunotherapy[J]. J Immunother Cancer, 2020, 8(2): e000957. |
[41] |
CHO B C,, ABREU D R,, HUSSEIN M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study[J]. Lancet Oncol, 2022, 23(6): 781-792.
doi: 10.1016/S1470-2045(22)00226-1 |
[42] |
MARIN-ACEVEDO J A,, KIMBROUGH E O,, LOU Y Y. Next generation of immune checkpoint inhibitors and beyond[J]. J Hematol Oncol, 2021, 14(1): 45.
doi: 10.1186/s13045-021-01056-8 |
[43] |
PAZ-ARES L,, KIM T M,, VICENTE D, et al. Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial[J]. J Thorac Oncol, 2020, 15(7): 1210-1222.
doi: 10.1016/j.jtho.2020.03.003 |
[44] | WU L,, CHEN B,, YAO W, et al. A phase Ⅰb/Ⅱ trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC[J]. Ann Oncol, 2021, 32: S1006. |
[45] |
HONG M H,, CLUBB J D,, CHEN Y Y. Engineering CAR-T cells for next-generation cancer therapy[J]. Cancer Cell, 2020, 38(4): 473-488.
doi: 10.1016/j.ccell.2020.07.005 |
[46] |
QU J J,, MEI Q H,, CHEN L J, et al. Chimeric antigen receptor (CAR)-T-cell therapy in non-small cell lung cancer (NSCLC): current status and future perspectives[J]. Cancer Immunol Immunother, 2021, 70(3): 619-631.
doi: 10.1007/s00262-020-02735-0 |
[47] |
YILMAZ A,, CUI H W,, CALIGIURI M A, et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy[J]. J Hematol Oncol, 2020, 13(1): 168.
doi: 10.1186/s13045-020-00998-9 |
[48] |
GOULDING J,, BLUM R,, HANCOCK B, et al. Abstract 1591: FT536: preclinical development of a novel off-the-shelf CAR-MICA/B NK cell immunotherapy combined with radiation and antibody treatments as a first-of-kind pan-cancer targeting strategy[J]. Cancer Res, 2021, 81(13_Supplement): 1591.
doi: 10.1158/1538-7445.AM2021-1591 |
[49] |
HEMMINKI O,, DOS SANTOS J M,, HEMMINKI A. Oncolytic viruses for cancer immunotherapy[J]. J Hematol Oncol, 2020, 13(1): 84.
doi: 10.1186/s13045-020-00922-1 |
[50] |
SAXENA M,, VAN DER BURG S H,, MELIEF C J M, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378.
doi: 10.1038/s41568-021-00346-0 |
[1] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[2] | ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising [J]. China Oncology, 2022, 32(8): 698-704. |
[3] | XU Yuchen, CHENG Leilei, WANG Yan, LIN Jinyi, CHEN Jiahui, CHEN Yifan, ZHOU Yuhong, LIU Tianshu, GE Junbo. Predictive value of sST2 level in immune-related adverse events [J]. China Oncology, 2022, 32(8): 712-718. |
[4] | HE Liyuan, WANG Yudong. Research progress of ALK kinase domain drug resistance mutation and its future countermeasures [J]. China Oncology, 2022, 32(8): 736-746. |
[5] | CHEN Yifan, CHENG Leilei, SHEN Yihui, ZHANG Hui, WANG Xuejun, XU Yuchen, GE Junbo. Establishment of a mouse myocarditis model induced by programmed death-1 inhibitor [J]. China Oncology, 2022, 32(7): 606-613. |
[6] | HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu. Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(7): 624-634. |
[7] | WU Jianhui, CHU Xiangling, WANG Liqiang, LIN Xinqing, XIE Xiaohong, XIE Mengqing, ZHAO Jing, DENG Haiyi, YANG Yilin, QIU Guihuan, ZHOU Maolin, SUN Ni, LI Ru, CHEN Ying, DENG Jiaxi, ZENG Chen, PAN Bolin, QIN Yinyin, LIU Ming, SU Chunxia, ZHOU Chengzhi. Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer [J]. China Oncology, 2022, 32(6): 469-477. |
[8] | YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498. |
[9] | JIANG Jianyun, YING Hongmei. Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma [J]. China Oncology, 2022, 32(5): 445-450. |
[10] | SU Jiaqi, XU Wenhao, TIAN Xi, ANWAIE Aihetaimujiang, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. New strategies for combined with immunotherapy of clear cell renal cell carcinoma: advances in aerobic glycolysis [J]. China Oncology, 2022, 32(4): 287-297. |
[11] | FU Yuanyuan, HOU Runping, FU Xiaolong. Research progress in predicting the risk of lymphatic or hematologic metastasis based on chest CT in early non-small cell lung cancer [J]. China Oncology, 2022, 32(4): 343-350. |
[12] | CHEN Guangliang, WU Fangtian, CAO Junning. Advances in research on EBV positive diffuse large B-cell lymphoma, not otherwise specified [J]. China Oncology, 2022, 32(3): 258-267. |
[13] | ZHU Yihui, LI Ting, HU Xichun. Clinical research progress and prospect of trastuzumab deruxtecan [J]. China Oncology, 2021, 31(8): 754-761. |
[14] | LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun . miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene [J]. China Oncology, 2021, 31(7): 581-588. |
[15] | YANG Jia , LIU Shuyuan , WANG Yingying , LI Yingfu , MA Qianli , LI Yu , WANG Yongrong , LI Chuanyin , TAN Fang . The association of polymorphisms in TNF-α gene with non-small cell lung cancer in Han population of Yunnan Province [J]. China Oncology, 2021, 31(7): 616-628. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd